FDA Pre-Emption Wins On Appeal

Lawsuits brought against GlaxoSmithKline and Pfizer over "failure to warn" claims for their antidepressant drugs are pre-empted by FDA's authority over labeling, the Third Circuit U.S. Court of Appeals has ruled. But industry's liability risks will likely be determined more by an upcoming Supreme Court case